Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
SystImmune Inc.
About
  2. Companies
  3. SystImmune Inc.
  4. Products
  5. SystImmune - Model BL-B01D1-ADC - ...

SystImmune - Model BL-B01D1-ADC -Specificity Enhanced Bi-specific Antibody (SEBA) Molecules

SHARE
Built on the foundation of Specificity Enhanced Bi-specific Antibody (SEBA) molecules the SEBA-ADC have an advanced mechanism of action. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and exert bi-modal proliferative inhibition, any cancer cell clones attempting proliferative escape are exposed to topoisomerase inhibition and die when attempting to duplicate.
Most popular related searches
cancer cell
cancer cell targeting
solid tumor
clinical trial
cancerous target
cancer specific
patient enrollment

The tetravalent HIRE BL-B01D1 has two binding domains for distinct Growth Factor Receptors that drive cancer cell proliferation and survival. Inheriting the SI-B001 mechanisms of action, BL-B01D1 blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals.  Upon antibody mediated internalization, BL-B01D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induced genotoxic stress activating pathways leading to cancer cell death.  

BL-B01D1 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of EGFR+ and HER3+ solid tumor indications.